Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials

BACKGROUND: Duvelisib is the first FDA-approved oral dual inhibitor of phosphatidylinositol-3-kinase PI3K-delta (PI3K-δ) and PI3K-gamma (PI3K-γ). Although many clinical studies support the efficacy of duvelisib, the safety of duvelisib remains with great attention. This systematic review and meta-an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhongwang, Zhou, Hui, Xu, Jing, Wang, Jinjin, Niu, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845779/
https://www.ncbi.nlm.nih.gov/pubmed/36685572
http://dx.doi.org/10.3389/fimmu.2022.1070660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845779/
https://www.ncbi.nlm.nih.gov/pubmed/36685572
http://dx.doi.org/10.3389/fimmu.2022.1070660

Ejemplares similares